Effect of Aripiprazole on Cognition in the Treatment of Patients with Schizophrenia

Overview

Journal Pharmacopsychiatry

Specialties Pharmacology
Psychiatry

Date 2010 Mar 26

PMID 20336597

Citations 19

Authors

M Riedel

I Spellmann

R Schennach-Wolff

R Musil

S Dehning

A Cerovecki

M Opgen-Rhein

J Matz

F Seemuller

M Obermeier

E Severus

R R Engel

N Muller

H-J Moller

Affiliations

Soon will be listed here.

Abstract

Background: The aim of this study was to assess the cognitive effects of aripiprazole in inpatients with schizophrenia.

Methods: This was an investigator-initiated, open label eight-week trial evaluating 56 inpatients with the DSM-IV diagnosis of schizophrenia. Efficacy was assessed weekly using the Positive and Negative Syndrome Scale (PANSS) and tolerability was assessed each week using the Udvalg for Klinske Undersogelser side effect rating scale (UKU). Cognitive function was assessed at baseline, week 4 and week 8.

Results: Aripiprazole showed significant improvement in PANSS total score and all subscores between baseline and endpoint visit. The substance was very well tolerated. Patients improved significantly in verbal memory, reaction time and reaction quality/attention from baseline to week eight. Furthermore, mean z-values of individual cognitive domains summarized in a global cognitive index improved significantly from baseline to week eight.

Discussion: Our results suggest that aripiprazole provides a valuable treatment option for patients with schizophrenia.

Citing Articles

Comparative effectiveness of aripiprazole and olanzapine on neurocognitive profile of patients with schizophrenia.

Sharma S, Sidana A, Mehta S, Bajaj M Indian J Psychiatry. 2023; 65(10):1044-1051.

PMID: 38108052 PMC: 10725211. DOI: 10.4103/indianjpsychiatry.indianjpsychiatry_303_23.

Novel Multimodal Salicylamide Derivative with Antidepressant-like, Anxiolytic-like, Antipsychotic-like, and Anti-Amnesic Activity in Mice.

Zmudzka E, Lustyk K, Gluch-Lutwin M, Wolak M, Jaskowska J, Kolaczkowski M Pharmaceuticals (Basel). 2023; 16(2).

PMID: 37259325 PMC: 9967428. DOI: 10.3390/ph16020175.

Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study.

Llorca P, Nuss P, Fakra E, Alamome I, Drapier D, El Hage W BMC Psychiatry. 2022; 22(1):364.

PMID: 35643542 PMC: 9142729. DOI: 10.1186/s12888-022-04008-9.

Differential Effects of Aripiprazole and Amisulpride on Negative and Cognitive Symptoms in Patients With First-Episode Psychoses.

Nielsen M, Kristensen T, Borup Bojesen K, Glenthoj B, Lemvigh C, Ebdrup B Front Psychiatry. 2022; 13:834333.

PMID: 35370857 PMC: 8969108. DOI: 10.3389/fpsyt.2022.834333.

Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial.

Gupta B, Chee K, Neo L, Tang C, Hariram J, Tan G Ther Adv Psychopharmacol. 2021; 11:20451253211046765.

PMID: 34646440 PMC: 8504280. DOI: 10.1177/20451253211046765.